Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer：a Prospective, Non-inferior, Randomized, Controlled Trial

NCT04922853 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT04922853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer：a Prospective, Non-inferior, Randomized, Controlled Trial
Lead sponsor
West China Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 26, 2021
Completion date
December 1, 2027
Enrollment
554 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant chemotherapy, rectal cancer